Concepedia

Publication | Open Access

Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials

DOIFull Paper Access

66

Citations

33

References

2019

Year

Kausik K. Ray, Antonio J. Vallejo‐Vaz, Henry N. Ginsberg, Michael H. Davidson, Michael J. Louie, Maja Bujas‐Bobanovic, Pascal Minini, Robert H. Eckel, Christopher P. Cannon
Atherosclerosis

References

YearCitations

Page 1